Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.

Luis E AguirreAkriti JainSomedeb BallNajla Al AliVirginia O VolpeSara Tinsley-VanceDavid SallmanKendra SweetJeffrey LancetEric PadronSeongseok YunAndrew KuykendallRami Komrokji

Published in: Clinical lymphoma, myeloma & leukemia (2024)

TN-MF is invariably associated with significantly decreased survival and more aggressive clinical behavior with higher rates of leukemic transformation and shorter duration of response to ruxolitinib. Mutations impacting RNA splicing, epigenetic modification and signaling (SRSF2, SETBP1, IDH2, CBL, and GNAS) are more common in TN-MF, which likely drive its aggressive course and may account for suboptimal responses to JAK inhibition.

Keyphrases

gene expression
dna methylation
acute myeloid leukemia
low grade
type diabetes
free survival
skeletal muscle